Shares of Boston-based resTORbio (NASDAQ: TORC) have nearly doubled to roughly $16 apiece, based on positive results the company released this morning from a Phase 2b trial of its drug for respiratory tract infections.
The drug, RTB101, is a pill that blocks an enzyme called TORC1. The company says the drug works by boosting immune function, along with other benefits. ResTORbio licensed the drug from Novartis last year.
The randomized, placebo-controlled 16-week trial included 652 elderly patients at risk of potentially fatal respiratory tract infections (RTIs). The company said that it had hit its main goal in the trial, showing… Read more »
UNDERWRITERS AND PARTNERS